ArticleCancer reports (Hoboken, N.J.)2022

Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.

Katherine A Lawson-Michod et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.